TippingPoint Biosciences is a biotechnology startup founded in 2022 with a focus on pioneering treatments for diseases related to genome packaging, particularly hard-to-treat cancers. The company is led by co-founders Dr. Laura Hsieh and Dr. Geeta J. Narlikar, both highly esteemed in their respective fields. With a recent Seed Round investment at 13 June 2023, SOSV and indiebio have shown confidence in the potential of TippingPoint's innovative approach.
Based in San Francisco, the startup has developed a novel drug discovery platform to target diseases caused by defects in DNA packaging, a unique focus that sets them apart from traditional pharmaceutical companies. TippingPoint's approach disrupts or restores the biological networks that package cell genomes, addressing the challenges often faced in healthcare. The company's mission to create an entirely new class of drugs to treat diseases represents a promising opportunity in the biotechnology sector.
For more information, visit https://tippingpointbiosciences.com/.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 2 |
|
13 Jun 2023 |
No recent news or press coverage available for TippingPoint Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
